Allogene Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Allogene Therapeutics, Inc. (ALLO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ALLO insiders buying or selling?
In the last 12 months, Allogene Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 15 sales ($666.3K) — net selling of $666.3K. Since October 2018, Trabud has recorded 99 Form 4 filings for ALLO: 11 buys ($27.8M) and 88 sells ($147.5M).
Source: SEC EDGAR Form 4
Key Statistics (October 2018 – Aug 25, 2026)
Total Form 4 filings
99
SEC EDGAR
Insider filers
19
Insider buys (11)
$27.8M
Insider sells (88)
$147.5M
Insider sentiment
Net sellingNet insider flow of $119.7M in net selling since October 2018, and $666.3K in net selling over the last 12 months.
Recent ALLO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Earl Martin Douglas | SVP, General Counsel | Sale | 29.7K | $2.12 | $63.0K | SEC ↗ |
| Apr 23, 2026 | Annie Yoshiyama | SVP, Finance | Sale | 9.6K | $2.31 | $22.1K | SEC ↗ |
| Apr 2, 2026 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale | 2.9K | $2.50 | $7.2K | SEC ↗ |
| Mar 18, 2026 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale | 4.8K | $2.47 | $11.9K | SEC ↗ |
| Mar 18, 2026 | Chang David D | President and CEO | Sale | 47.8K | $2.47 | $118.0K | SEC ↗ |
| Mar 4, 2026 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale | 7.1K | $2.60 | $18.5K | SEC ↗ |
| Feb 4, 2026 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale | 7.5K | $1.73 | $13.1K | SEC ↗ |
| Feb 4, 2026 | Chang David D | President and CEO | Sale | 95.3K | $1.80 | $171.5K | SEC ↗ |
| Feb 4, 2026 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sale | 24.0K | $1.76 | $42.2K | SEC ↗ |
| Feb 4, 2026 | Earl Martin Douglas | SVP, General Counsel | Sale | 22.9K | $1.76 | $40.3K | SEC ↗ |
| Feb 4, 2026 | Annie Yoshiyama | SVP, Finance | Sale | 4.2K | $1.72 | $7.2K | SEC ↗ |
| Feb 4, 2026 | Zachary Roberts | EVP of R&D | Sale | 35.7K | $1.77 | $63.2K | SEC ↗ |
| Jan 23, 2026 | Zachary Roberts | EVP of R&D | Sale | 26.3K | $1.56 | $41.0K | SEC ↗ |
| Nov 19, 2025 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale | 786 | $1.22 | $958.92 | SEC ↗ |
| Oct 23, 2025 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sale | 36.7K | $1.26 | $46.2K | SEC ↗ |
| Jun 12, 2025 | Deborah M. Messemer | Director | Sale | 36.9K | $1.42 | $52.4K | SEC ↗ |
| Apr 23, 2025 | Annie Yoshiyama | SVP, Finance | Sale | 9.6K | $1.41 | $13.5K | SEC ↗ |
| Mar 18, 2025 | Chang David D | President and CEO | Sale | 46.7K | $1.96 | $91.5K | SEC ↗ |
| Mar 18, 2025 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale | 5.5K | $1.98 | $10.8K | SEC ↗ |
| Feb 20, 2025 | Deborah M. Messemer | Director | Sale | 13.3K | $2.43 | $32.4K | SEC ↗ |
| Feb 5, 2025 | Earl Martin Douglas | SVP, General Counsel | Sale | 6.4K | $1.71 | $11.0K | SEC ↗ |
| Feb 5, 2025 | Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | Sale | 4.4K | $1.73 | $7.5K | SEC ↗ |
| Feb 5, 2025 | Timothy L. Moore | Chief Technical Officer | Sale | 14.7K | $1.71 | $25.2K | SEC ↗ |
| Feb 5, 2025 | Chang David D | President and CEO | Sale | 46.0K | $1.68 | $77.3K | SEC ↗ |
| Feb 5, 2025 | Zachary Roberts | EVP of R&D | Sale | 18.8K | $1.70 | $32.0K | SEC ↗ |
Showing the 25 most recent of 99 Form 4 filings for Allogene Therapeutics, Inc..
Most active ALLO insiders
- Veer Bhavnagri15 filings
- Alison Moore9 filings
- Rafael Amado9 filings
- Chang David D8 filings
- David Bonderman8 filings
Ask anything about ALLO insider activity
Use Trabud's AI agent to query Allogene Therapeutics, Inc.'s Form 4 history in plain English — "Show me ALLO CEO purchases this year" or compare it against any other ticker.
Open the AI agentALLO insider trading FAQ
Are Allogene Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Allogene Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 15 sales ($666.3K) — net selling of $666.3K. Since October 2018, Trabud has recorded 99 Form 4 filings for ALLO: 11 buys ($27.8M) and 88 sells ($147.5M). Over the full record that is net selling of $119.7M.
How many insiders trade ALLO stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Allogene Therapeutics, Inc.. The most recent filing was accepted on Aug 25, 2026.
Where does Trabud get ALLO insider trading data?
All ALLO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.